BioNTech Shares Under Pressure as FDA Memo Sparks Sector-Wide Selloff

December has opened with a jolt for BioNTech and its investors. A strategic pivot toward oncology and a critical acquisition are now overshadowed by regulatory tremors emanating from the United States. An internal memo from the U.S. Food and Drug Administration (FDA) has sent shockwaves through the biotechnology sector, raising urgent questions about the company’s near-term trajectory amid mounting challenges.

The immediate catalyst for a sharp sector decline was a document from Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER). The memo discusses a potential link between COVID-19 vaccines and fatal myocarditis, or heart inflammation, in children. It cites at least ten such Read more...